Abstract
Background More than 2.5 billion people in the world are currently in lockdowns to limit the spread of the novel coronavirus disease 2019 (COVID-19). Psychological Distress (PD) and Post-Traumatic Stress Disorder have been reported after traumatic events, but the specific effect of pandemics is not well known.
Objectives The aim of this study was to assess PD in France, a country where COVID-19 had such a dramatic impact that it required a country-wide lockdown.
Methods This study was a survey conducted in France between 31 March 2020 and 7 April 2020. We recruited patients in 4 groups of chatbot users followed for breast cancer, asthma, depression and migraine. We used the Psychological Distress Index (PDI), a validated scale to measure PD during traumatic events, and correlated PD risk with patients’ characteristics in order to better identify the one who were the most at-risk.
Results The study included 1771 participants. 91.25% (1616) were female with a mean age of 32.8 years (SD=13,71), 7.96% (141) were male with a mean age of 28.0 years (SD=8,14). In total, 38.06% (674) of the respondents had psychological distress (PDI ≥15). An ANOVA analysis showed that sex (p=0.00132), unemployment (p=7.16×10-6) and depression (p=7.49×10-7) were significantly associated with a higher PDI score. Patients using their smartphone or computer more than one hour a day also had a higher PDI score (p=0.02588).
Conclusion Prevalence of PD in at-risk patients is high. These patients are also at increased risk to develop Post-Traumatic Stress Disorder. Specific steps should be implemented to monitor and prevent PD through dedicated mental health policies if we want to limit the public health impact of COVID-19 in time.
Competing Interest Statement
GD, AG and BB are employed by Wefight. BC and JEB own shares of Wefight.
Clinical Trial
NCT04337047
Funding Statement
Research supported by Wefight.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
BC had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
